Publication Date
1-1-2022
Journal
PLoS One
DOI
10.1371/journal.pone.0264674
PMID
35617270
PMCID
PMC9135258
PubMedCentral® Posted Date
5-26-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Arachis, Child, Dendritic Cells, Desensitization, Immunologic, Humans, Peanut Hypersensitivity, Phenotype
Abstract
Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. We analyzed dendritic cells in 15 pediatric subjects (5-12 years) undergoing a phase 1 single-center POIT study. We examined dendritic cells at baseline, 6-, 12-, 18- and 24-weeks after initiation of POIT and responders of therapy were compared to non-responders and healthy controls. The distribution frequency of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) from peripheral blood samples were measured in vitro. A general linear mixed model was used, and included fixed effects for cohort (responder, non-responder, or healthy control), time (0-, 6-, 12-, 18-, and 24-weeks), and the cohort-time interaction term. P-values were adjusted for multiple hypothesis testing using Tukey's method. We observed that POIT responders had reduced TNFa producing myeloid dendritic cells (mDCs) compared to non-responders. Additionally, non-responders had increased OX40L expressing mDCs at 18-weeks compared to responders. In conclusion, our findings suggest that a reduced pro-inflammatory phenotype in DCs could potentially serve as a predictor of early outcome and success of POIT desensitization.
Included in
Immunology of Infectious Disease Commons, Immunopathology Commons, Immunotherapy Commons, Medical Immunology Commons, Pathology Commons